Form 4: Provectus Biopharmaceuticals CEO Acquires Convertible Note

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $75,000, convertible into Series D-1 Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), acquired an 8% unsecured convertible promissory note.
• The principal amount of the note acquired is $75,000.
• The note is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The note was issued pursuant to the Issuer's 2025 Financing.
• The note can be voluntarily converted at any time or will automatically convert into Series D-1 Preferred Stock on December 5, 2026.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted.
• Following this transaction, Edward Pershing beneficially owns 26,206 shares of Series D-1 Convertible Preferred Stock directly.
• The filing also indicates beneficial ownership of $1,420,000 in derivative securities related to the note following the reported transaction.

Sentiment

Score: 6

Explanation: The CEO's personal investment is a positive signal of confidence in the company's future. However, the use of an 8% unsecured convertible note for financing suggests the company might be facing challenges in securing less dilutive or lower-cost capital, and the potential for future dilution exists, balancing the overall sentiment.

Positives

• CEO Edward Pershing's acquisition of the convertible note demonstrates continued investment and confidence in the company's future prospects.
• The note is part of the company's 2025 Financing, indicating ongoing capital raising efforts to support operations.

Negatives

• The acquisition of a convertible note by the CEO, while an insider investment, could also signal a need for capital that might lead to future dilution for existing common shareholders upon conversion.
• The 8% interest rate on the unsecured note suggests a relatively high cost of capital for the company, potentially reflecting perceived risk or limited access to lower-cost financing.

Risks

• Potential future dilution for common stockholders if the Series D-1 Preferred Stock, into which the note converts, is subsequently converted into common stock.
• The company's reliance on convertible notes for financing may indicate challenges in securing less dilutive forms of capital.
• The 8% interest rate on the unsecured note represents a financial obligation for the company that impacts its cash flow and profitability.

Future Outlook

The company's 2025 Financing, which includes the issuance of this convertible note, suggests ongoing efforts to secure capital for future operations. The conversion terms indicate a potential future increase in common stock outstanding, impacting the company's equity structure and potentially leading to dilution.

Management Comments

• The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the 'Note') at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ('Series D-1 Preferred Stock') at a price per share equal to $2.862.
• The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note.
• The Note was issued pursuant to the Issuer's 2025 Financing.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ('Common Stock').
• The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

Industry Context

In the biopharmaceutical sector, companies often rely on various financing mechanisms, including convertible notes and preferred stock, to fund research, development, and clinical trials. Insider purchases, especially by top executives, can signal confidence in a company's pipeline or strategic direction. However, the terms of the financing, such as an 8% unsecured note, also reflect the company's current financial standing and access to capital markets, which can be more challenging for smaller or development-stage biotechs.

Comparison to Industry Standards

• NA

Related Party Transactions

• Edward Pershing, as CEO and Director of Provectus Biopharmaceuticals, Inc., acquiring a convertible note from the company constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution of common stock upon conversion of the Series D-1 Preferred Stock into common shares. The CEO's investment could be seen as a positive signal of confidence.
• Creditors: The unsecured nature of the 8% convertible note places it lower in the capital structure compared to secured debt, potentially increasing risk for other creditors.

Next Steps

• Potential voluntary conversion of the 8% unsecured convertible promissory note into Series D-1 Preferred Stock by Edward Pershing.
• Automatic conversion of the note into Series D-1 Preferred Stock on December 5, 2026, if not converted earlier.
• Automatic conversion of Series D-1 Preferred Stock into Common Stock on June 26, 2026, if not converted earlier.

Key Dates

Recommendation

While the CEO's acquisition of a convertible note signals confidence, the 8% unsecured nature of the note and the potential for future dilution from its conversion into preferred and then common stock introduce elements of risk. The transaction is part of a broader 2025 financing, suggesting ongoing capital needs. Investors should hold and monitor the company's operational performance, future financing activities, and the impact of potential dilution before making further investment decisions.

Keywords

Provectus Biopharmaceuticals, PVCT, SEC Form 4, Insider Trading, Convertible Note, Series D-1 Preferred Stock, Equity Financing, CEO Investment, Biopharmaceutical